Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease

Authors

  • Teri R. Thomsen MD,

    1. Movement Disorders Centre, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada
    Search for more papers by this author
  • Wendy R. Galpern MD, PhD,

    1. Movement Disorders Centre, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada
    Current affiliation:
    1. NINDS/NIH, Bethesda, MD, USA
    Search for more papers by this author
  • Abena Asante MSc,

    1. Movement Disorders Centre, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada
    Search for more papers by this author
  • Tamara Arenovich MSc,

    1. Biostatistical Consulting Service, Clinical Research Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Search for more papers by this author
  • Susan H. Fox MRCP(UK), PhD

    Corresponding author
    1. Movement Disorders Centre, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada
    • MCL7.421, Movement Disorders Clinic, Toronto Western Hospital, 399 Bathurst St, Toronto, Ontario, M5T 2S8, Canada
    Search for more papers by this author

Abstract

Sialorrhea is a significant problem in advanced Parkinson's disease (PD). Current treatment options include systemic anticholinergics which frequently cause side effects. We hypothesized that sublingual application of ipratropium bromide spray, an anticholinergic agent that does not cross the blood brain barrier, may reduce drooling without systemic side effects. We performed a randomized, double blind, placebo-controlled, crossover study in 17 subjects with PD and bothersome drooling. Patients were randomized to receive ipratropium bromide or placebo (one to two sprays, maximum of four times per day) for 2 weeks followed by a 1 week washout and crossover for further 2 weeks of treatment. The primary outcome was an objective measure of weight of saliva production. Secondary outcomes were subjective rating of severity and frequency of sialorrhoea using home diaries, United Parkinson's Disease Rating Scale (UPDRS) part II salivation subscore, parkinsonian disability using UPDRS, and adverse events. Ipratropium bromide spray had no significant effect on weight of saliva produced. There was a mild effect of treatment on subjective measures of sialorrhea. There were no significant adverse events. Ipratropium bromide spray was well tolerated in subjects with PD. Although it did not affect objective measures of saliva production, further studies in parkinsonism may be warranted. © 2007 Movement Disorder Society

Ancillary